Your browser doesn't support javascript.
loading
A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models.
van Lengerich, Bettina; Zhan, Lihong; Xia, Dan; Chan, Darren; Joy, David; Park, Joshua I; Tatarakis, David; Calvert, Meredith; Hummel, Selina; Lianoglou, Steve; Pizzo, Michelle E; Prorok, Rachel; Thomsen, Elliot; Bartos, Laura M; Beumers, Philipp; Capell, Anja; Davis, Sonnet S; de Weerd, Lis; Dugas, Jason C; Duque, Joseph; Earr, Timothy; Gadkar, Kapil; Giese, Tina; Gill, Audrey; Gnörich, Johannes; Ha, Connie; Kannuswamy, Malavika; Kim, Do Jin; Kunte, Sebastian T; Kunze, Lea H; Lac, Diana; Lechtenberg, Kendra; Leung, Amy Wing-Sze; Liang, Chun-Chi; Lopez, Isabel; McQuade, Paul; Modi, Anuja; Torres, Vanessa O; Nguyen, Hoang N; Pesämaa, Ida; Propson, Nicholas; Reich, Marvin; Robles-Colmenares, Yaneth; Schlepckow, Kai; Slemann, Luna; Solanoy, Hilda; Suh, Jung H; Thorne, Robert G; Vieira, Chandler; Wind-Mark, Karin.
Afiliación
  • van Lengerich B; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Zhan L; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Xia D; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Chan D; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Joy D; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Park JI; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Tatarakis D; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Calvert M; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Hummel S; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Lianoglou S; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.
  • Pizzo ME; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Prorok R; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Thomsen E; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Bartos LM; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Beumers P; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.
  • Capell A; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.
  • Davis SS; Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
  • de Weerd L; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Dugas JC; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Duque J; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Earr T; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Gadkar K; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Giese T; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Gill A; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Gnörich J; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Ha C; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.
  • Kannuswamy M; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Kim DJ; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Kunte ST; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Kunze LH; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.
  • Lac D; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Lechtenberg K; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.
  • Leung AW; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Liang CC; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Lopez I; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • McQuade P; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Modi A; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Torres VO; Takeda Pharmaceutical Company, Cambridge, MA, USA.
  • Nguyen HN; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Pesämaa I; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Propson N; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Reich M; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Robles-Colmenares Y; Graduate School of Systemic Neurosciences, Ludwig Maximilians University Munich, Planegg-Martinsried, Germany.
  • Schlepckow K; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Slemann L; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Solanoy H; Graduate School of Systemic Neurosciences, Ludwig Maximilians University Munich, Planegg-Martinsried, Germany.
  • Suh JH; Denali Therapeutics, Inc., South San Francisco, CA, USA.
  • Thorne RG; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Vieira C; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.
  • Wind-Mark K; Denali Therapeutics, Inc., South San Francisco, CA, USA.
Nat Neurosci ; 26(3): 416-429, 2023 03.
Article en En | MEDLINE | ID: mdl-36635496

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Pluripotentes Inducidas / Enfermedad de Alzheimer Límite: Animals / Humans Idioma: En Revista: Nat Neurosci Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Pluripotentes Inducidas / Enfermedad de Alzheimer Límite: Animals / Humans Idioma: En Revista: Nat Neurosci Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos